Abstract
To the Editor: Dupilumab, a monoclonal antibody that blocks T helper type 2 cytokines,1-4 is approved for the treatment of cutaneous manifestations of atopic dermatitis. Unfortunately, dupilumab use can result in ophthalmic complications. In the inaugural phase 3 clinical trials, 14% to 19% of patients reported dupilumab-associated conjunctivitis but were not examined by an ophthalmologist.1,4 Thus, it is possible that some of these patients could have experienced a more severe form of ocular surface disease than simple reactive conjunctivitis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
